TAXUS Liberté Attenuates the Risk of Restenosis in Patients With Medically Treated Diabetes Mellitus
Results From the TAXUS ATLAS Program
Ehtisham Mahmud, John A. Ormiston, Mark A. Turco, Jeffrey J. Popma, Neil J. Weissman, Charles D. O'Shaughnessy, Tift Mann, Jack J. Hall, Thomas F. McGarry, Louis A. Cannon, Mark W.I. Webster, Lazar Mandinov and Donald S. Baim
The frequency of individual patterns of in-stent restenosis (ISR) in subjects with and without diabetes treated with the TAXUS Liberté Stent in TAXUS ATLAS studies. Intent-to-treat, angiographic subset (n = 1,201; diabetic: 334; nondiabetic: 867).